Compare NRIM & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRIM | SCTX |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.6M | 536.5M |
| IPO Year | 2002 | 2026 |
| Metric | NRIM | SCTX |
|---|---|---|
| Price | $25.16 | $28.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 103.6K | ★ 220.5K |
| Earning Date | 04-22-2026 | N/A |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $255,581,000.00 | N/A |
| Revenue This Year | $4.98 | N/A |
| Revenue Next Year | $7.40 | N/A |
| P/E Ratio | $19.55 | ★ N/A |
| Revenue Growth | ★ 30.43 | N/A |
| 52 Week Low | $19.60 | $17.31 |
| 52 Week High | $30.82 | $39.60 |
| Indicator | NRIM | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.78 | 49.37 |
| Support Level | $24.87 | $27.41 |
| Resistance Level | $25.45 | $39.60 |
| Average True Range (ATR) | 0.56 | 3.41 |
| MACD | -0.07 | -0.40 |
| Stochastic Oscillator | 3.87 | 34.66 |
Northrim BanCorp Inc is a bank holding company operating through three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. The Community Banking segment, which generates the majority of revenue, provides loan and deposit products to business and consumer customers in its market areas. The Home Mortgage Lending segment focuses on the origination and sale of mortgage loans for one-to-four family residential properties, mortgage loan servicing for certain loans sold, and investment in selected residential mortgage loans. The Specialty Finance segment provides factoring, asset-based lending, and alternative working capital solutions to small and medium-sized enterprises and includes SCF and Northrim Funding Services.
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.